Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Current Deferred Revenue (2016 - 2022)

Agios Pharmaceuticals (AGIO) has disclosed Current Deferred Revenue for 9 consecutive years, with $2.5 million as the latest value for Q1 2022.

  • For the quarter ending Q1 2022, Current Deferred Revenue changed N/A year-over-year to $2.5 million, compared with a TTM value of $2.5 million through Mar 2022, changed N/A, and an annual FY2019 reading of $61.5 million, up 88.06% over the prior year.
  • Current Deferred Revenue was $2.5 million for Q1 2022 at Agios Pharmaceuticals, down from $4.7 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $61.5 million in Q4 2019 and bottomed at $686000.0 in Q3 2018.
  • Average Current Deferred Revenue over 4 years is $20.0 million, with a median of $17.7 million recorded in 2019.
  • The sharpest move saw Current Deferred Revenue crashed 80.87% in 2018, then surged 2359.62% in 2019.
  • Year by year, Current Deferred Revenue stood at $32.7 million in 2018, then skyrocketed by 88.06% to $61.5 million in 2019, then plummeted by 92.28% to $4.7 million in 2020, then plummeted by 47.35% to $2.5 million in 2022.
  • Business Quant data shows Current Deferred Revenue for AGIO at $2.5 million in Q1 2022, $4.7 million in Q1 2020, and $61.5 million in Q4 2019.